Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing…
